Enovis CORPENOV财报
Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.
ENOV Q4 2025 Key Financial Metrics
营收
$548.9M
毛利润
$328.9M
营业利润
$-558.5M
净利润
$-571.1M
毛利率
59.9%
营业利润率
-101.7%
净利率
-104.1%
同比增长
-2.2%
EPS
$-9.99
资金流向
Enovis CORP Q4 2025 财务摘要
Enovis CORP reported revenue of $548.9M (down 2.2% YoY) for Q4 2025, with a net profit of $-571.1M (up 18.8% YoY) (-104.1% margin). Cost of goods sold was $220.0M, operating expenses totaled $887.4M.
核心财务指标
| 总营收 | $548.9M |
|---|---|
| 净利润 | $-571.1M |
| 毛利率 | 59.9% |
| 营业利润率 | -101.7% |
| 报告期 | Q4 2025 |
营收拆解
Enovis CORP Q4 2025 revenue of $548.9M breaks down across 4 segments, led by Reconstructive Segment at $258.0M (47.0% of total).
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Reconstructive Segment | $258.0M | 47.0% |
| Surgical | $129.0M | 23.5% |
| Prevention And Recovery | $92.6M | 16.9% |
| Other Prevention And Recovery | $71.4M | 13.0% |
Enovis CORP 分部营收 — 季度趋势
Enovis CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Reconstructive Segment and Surgical) has evolved quarter over quarter.
| 业务分部 | Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 |
|---|---|---|---|---|
| Reconstructive Segment | $258.0M | $274.0M | $286.3M | $274.0M |
| Surgical | $129.0M | — | — | — |
| Prevention And Recovery | $92.6M | $98.9M | $90.9M | $92.5M |
| Other Prevention And Recovery | $71.4M | $70.8M | $66.6M | $70.2M |
Enovis CORP 年度营收
Enovis CORP annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.1B). Click any linked year to see what changed vs the prior 10-K.
Enovis CORP 季度营收与净利润历史
Enovis CORP quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $548.9M | -2.2% | $-571.1M | -104.1% |
| Q3 2025 | $564.5M | +11.7% | $-36.7M | -6.5% |
| Q2 2025 | $558.8M | +6.4% | $-56.0M | -10.0% |
| Q4 2024 | $561.0M | +23.3% | $-703.2M | -125.4% |
| Q3 2024 | $505.2M | +21.0% | $-31.5M | -6.2% |
| Q2 2024 | $525.2M | +22.6% | $-18.6M | -3.5% |
| Q1 2024 | $516.3M | +27.1% | $-72.0M | -13.9% |
| Q4 2023 | $455.0M | +15.2% | $3.1M | 0.7% |
利润表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $455.0M | $516.3M | $525.2M | $505.2M | $561.0M | $558.8M | $564.5M | $548.9M |
| 同比增长 | 15.2% | 27.1% | 22.6% | 21.0% | 23.3% | 6.4% | 11.7% | -2.2% |
资产负债表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $4.51B | $5.48B | $5.44B | $5.55B | $4.72B | $4.88B | $5.02B | $4.43B |
| 总负债 | $1.09B | $2.17B | $2.15B | $2.22B | $2.15B | $2.25B | $2.44B | $2.41B |
| 股东权益 | $3.42B | $3.31B | $3.29B | $3.33B | $2.56B | $2.62B | $2.58B | $2.02B |
现金流量表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $68.4M | $-36.2M | $7.8M | $53.6M | $88.3M | $-1.6M | $47.8M | $82.6M |